|
Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study. |
| |
|
Honoraria - AstraZeneca; MSD; pfizer; pharmamar; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Pfizer; PharmaMar; Roche; tesaro |
Research Funding - AstraZeneca (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst) |
| |
|
(OPTIONAL) Uncompensated Relationships - Ozmosis Research |
| |
|
|
|
Consulting or Advisory Role - IQVIA (I) |
Research Funding - IQVIA (I) |
Travel, Accommodations, Expenses - IQVIA (I) |
| |
|
Consulting or Advisory Role - Clovis Oncology |
Travel, Accommodations, Expenses - Clovis Oncology; GlaxoSmithKline; MSD |
| |
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline |
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; GlaxoSmithKline |
Consulting or Advisory Role - Clovis Oncology; GlaxoSmithKline |
Travel, Accommodations, Expenses - GlaxoSmithKline |
| |
|
Employment - Sarepta Therapeutics (I) |
Honoraria - Advaxis; Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Novartis; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro |
Consulting or Advisory Role - Advaxis; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Nuvation Bio; Pfizer; Pfizer; Roche/Genentech; Tesaro |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - GlaxoSmithKline |
Speakers' Bureau - Clovis Oncology; GlaxoSmithKline; MSD; PharmaMar |
Research Funding - AstraZeneca; Roche |
| |
|
Consulting or Advisory Role - AstraZeneca; Roche; Tesaro/GSK; Tesaro/GSK; Tesaro/GSK |
Research Funding - Aprea AB (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - MSD; Pfizer |
| |
Rumyana Nedyalkova Ilieva |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Astellas Pharma; AstraZeneca; Eisai; Janssen; MSD Oncology; Novartis; Pfizer; Roche; Takeda |
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Janssen; MSD Oncology; Novartis; Pfizer; Roche; Takeda |
Research Funding - GlaxoSmithKline (Inst); Tesaro (Inst) |
| |
|
|
Stock and Other Ownership Interests - AstraZeneca |
| |
|
|
| |
|
|
Stock and Other Ownership Interests - AstraZeneca; OmniacPharmConsult |
| |
|
Consulting or Advisory Role - AstraZeneca; Eisai Europe; GlaxoSmithKline |
Speakers' Bureau - Clovis Oncology |
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Immunogen (Inst); Merck (Inst); Pfizer (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Tesaro |